Genentech presents RG7204 Phase II trial results
In the trial, people participated lived a median of 6.2 months without their disease getting worse (median progression-free survival or PFS). Almost 52% of patients in the trial
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.